Figure 6
From: Allogeneic dendritic cells induce potent antitumor immunity by activating KLRG1+CD8 T cells
AlloDC as therapeutic vaccine to treat residual cancer. (a) Schematic diagram of exploiting alloDC to treat mice with residual B16 cells. (b) 5 × 104, 5 × 103 or 5 × 102 B16 cells were pre-inoculated intravenously into recipient mice. After 24 hours, mice in therapeutic group were treated peritoneally with 1 × 106 DBA DC, while mice in control group were treated with PBS. The therapeutic DBA DC were injected every 7 days for three times. Survival rates of all mice were recorded and shown. (c) Photos of lung metastatic nodes of alloDC-treated and untreated mice pre-inoculated with 5 × 102 B16 cells were taken. (d) Statistics of lung metastatic nodes of alloDC-treated and untreated mice pre-inoculated with 5 × 102 B16 cells were shown. (e,f) Seven days after the 3rd immunization, peripheral blood lymphocytes of treated and untreated mice were collected, whose proportions of KLRG1+CD8 T cells in CD8 T cells were compared. Each experiment represents 1 out of 3 experiments. n = 5. (g,h) 1 × 104 B16 cells were injected intravenously into B6 mice. After 24 hours, mice in combination therapy group were firstly treated peritoneally with 1 × 106 DBA DC and then with 200 µg anti-PD1 on day 7, day 14 and day 21 post tumor inoculation. Mice in only alloDC or anti-PD1 treatment group were treated with the single drug as mentioned above. B16 lung metastasis (g) and the survival rates (h) of all mice were recorded and shown. These experiments were repeated for 3 times. n = 5 for each repeat. P values indicated the statistical significance when comparing with each monotherapy group.
